Alembic Pha Q3 PAT seen up 19.9% YoY to Rs. 280.9 cr: ICICI Direct

Net Sales are expected to increase by 17.7 percent Y-o-Y (down 2.4 percent Q-o-Q) to Rs. 1,422.8 crore, according to ICICI Direct.

India Inc’s profits to suffer hard knock from inventory losses – Part I

Alembic Pharma reports better numbers in Q3; here are highlights of analyst call

The company reported 33.8 percent jump in its Q3FY20 net profit to Rs 227.31 crore, EBITDA up 32.4 percent at Rs 325.46 crore

'Q2 review: Bet on these 13 stocks for strong growth in FY21'

Earnings downgrade continued in the September quarter but there were no fresh negatives in terms of outlook in management commentaries.

Alembic Pharma Q3 PAT seen up 7.7% YoY to Rs. 140.6 cr: ICICI Direct

Net Sales are expected to increase by 21.4 percent Y-o-Y (down 9.5 percent Q-o-Q) to Rs. 1019.5 crore, according to ICICI Direct.

Alembic Pharma Q2 PAT may dip 9.3% YoY to Rs. 110 cr: HDFC Securities

Net Sales are expected to increase by 18.8 percent Y-o-Y (up 8.7 percent Q-o-Q) to Rs. 940 crore, according to HDFC Securities.

Alembic Pharma Q2 PAT may dip 4.5% YoY to Rs. 116.1 cr: ICICI Direct

Net Sales are expected to increase by 20.7 percent Y-o-Y (up 10.4 percent Q-o-Q) to Rs. 952.3 crore, according to ICICI Direct.

Alembic Pharma Q4 PAT seen up 55.6% YoY to Rs. 148.3 cr: KR Choksey

Net Sales are expected to increase by 21.2 percent Y-o-Y (up 7 percent Q-o-Q) to Rs. 898.8 crore, according to KR Choksey.

Alembic Pharma Q4 PAT seen up 0.3% YoY to Rs. 90 cr: HDFC Securities

Net Sales are expected to increase by 6.3 percent Y-o-Y (down 6.6 percent Q-o-Q) to Rs. 780 crore, according to HDFC Securities.

Alembic Pharma Q1 PAT may dip 16.70% YoY to Rs 86.3 cr: KR Choksey

Net Sales are expected to decrease by 6.86 percent Q-o-Q (down 6.29 percent Y-o-Y) to Rs 689.5 crore, according to KR Choksey. Alembic Pharma to report net profit at 86.3 crore down 16.70% year-on-year.

Alembic Pharma Q4 PAT seen up 7.4% to Rs 92.9 cr: ICICI Securities

Net Sales are expected to increase by 2.6 percent Q-o-Q (up 26.3 percent Y-o-Y) to Rs 791.1 crore, according to ICICI Securities. Alembic Pharma to report net profit at 71.3 crore up 66.6% quarter-on-quarter.

Alembic Pharma Q3 profit seen down 60%, margin may shrink 20%

Alembic Pharmaceuticals is expected to show massive degrowth in third quarter earnings due to unfavourable base in year-ago quarter. Profit is likely to fall 60 percent year-on-year to Rs 107 crore and revenue may slip 14 percent to Rs 794 crore in Q3, according to average of estimates of analysts polled by CNBC-TV18.

Alembic Pharma Q3 PAT may dip 16% to Rs 100 cr: HDFC Securities

Net Sales are expected to decrease by 9.5 percent Q-o-Q (down 14.2 percent Y-o-Y) to Rs 790 crore, according to HDFC Securities.

Alembic Pharma Q3 PAT may dip 22% to Rs 94 cr: ICICI Securities

Net Sales are expected to decrease by 12.6 percent Q-o-Q (down 17.3 percent Y-o-Y) to Rs 762.3 crore, according to ICICI Securities.

Alembic Pharma Q3 PAT may dip 27.1% to Rs 87.3 cr: KR Choksey

Net Sales are expected to decrease by 18.4 percent Q-o-Q (down 22.1 percent Y-o-Y) to Rs 717.4 crore, according to KR Choksey.

We are planning 6-8 new launches this fiscal yr: Alembic Pharma

Speaking to CNBC-TV18 Pranav Amin, Managing Director of Alembic Pharmaceuticals, said that good Q1 numbers were led by international business. Sales of its anti-psychotic drug Abilify was one of the reasons the company saw higher sales, he said.

EBITDA margin came off unusually high base: Alembic Pharma

In an interview with CNBC-TV18‘s Ekta Batra and Reema Tendulkar, Pranav Amin, Director & President- International Business, Alembic Pharmaceuticals, discussed the company‘s quarterly earnings.

Alembic Pharma expects API biz to grow 10% in FY15

The growth for the international generics, however, remain muted at about 9 percent due to higher base last year.

See 20% EBITDA growth in FY14: Alembic Pharma

In an interview to CNBC-TV18, Amin adds that the company, despite the drug pricing policy, will grow at 15 percent.

See 100-120 bps margin improvement in FY14: Alembic Pharma

Alembic Pharma is hopeful to increase operating margin by 100-120 basis points in current financial year on the back of strong growth in international and domestic generic business.

See pharma sector's margins to dip 314 bps in 3QFY13: Angel

Angel Broking has come out with earning expectations for pharmaceutical sector for the October-December quarter of 2012. The research firm expects the Indian pharma sector to post lackluster numbers for 3QFY2013 on the sales front.

ANDAs will benefit FY13 and FY14 numbers: Alembic Pharma

Alembic Pharma has announced its third quarter results. Pranav Amin, director of Alembic Pharma says, the revenues have gone up 15%, YoY. He further says, the company so far has filed 41 abbreviated new drug applications (ANDAs). “Over the next couple of years, we should see quite a bit of growth coming in international generic,” he adds.